caa a22 4500 469074183 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01741747 doi (NATIONALLICENCE)springer-10.1007/BF01741747 Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen [Elektronische Daten] [Kelly Hunt, Masahiko Shibata, Rishab Gupta, Donald Morton] Summary: We developed a high-titer polyclonal antiserum to a glycoprotein tumor-associated antigen (TAA) by immunization of a baboon with the purified glycoprotein antigen. The baboon serum was fractionated into IgG and IgM components by DEAE Affi-Gel blue chromatography. The ability of the baboon IgM anti-TAA antibody to effect tumor cell lysis in the presence of complement was tested using a chromium-release assay. The baboon antibody was able to lyse melanoma target cells (20.8%-71.4% cytolysis), breast carcinoma cells (36.5%-38.9% cytolysis), and a neuroblastoma cell line (35.5% cytolysis) in the presence of complement but did not effect significant lysis of autologous lymphoblastoid cell lines (4.9% cytolysis) or peripheral blood lymphocytes from healthy volunteers (12.6% cytolysis). Cytolysis of melanoma target cells was completely inhibited by preabsorption of the IgM anti-TAA antibody with UCLA-SO-M14 (M14) cells and partially inhibited by preabsorption with several other melanoma cell lines. There was no significant inhibition of tumor cell lysis after preabsorption of the antibody with lymphoblastoid cell lines. Complement-dependent lysis of M14 targets could be blocked by addition of the purified antigen to the antibody prior to incubation with the tumor cells. Our results suggest that the glycoprotein TAA resides on the tumor cell surface and that the baboon IgM anti-TAA antibody recognizes the antigen on the cell surface and is able to fix complement and effect the lysis of the tumor cells. Springer-Verlag, 1992 Tumor-associated antigen nationallicence Complement-dependent cytotoxicity nationallicence Polyclonal antibodies nationallicence Monoclonal antibodies nationallicence Glycoprotein antigen nationallicence Hunt Kelly John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut Shibata Masahiko John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut Gupta Rishab John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut Morton Donald John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 377-382 0340-7004 34:6<377 1992 34 262 https://doi.org/10.1007/BF01741747 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741747 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hunt Kelly John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut NATIONALLICENCE 700 1- Shibata Masahiko John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut NATIONALLICENCE 700 1- Gupta Rishab John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut NATIONALLICENCE 700 1- Morton Donald John Wayne Institute for Cancer Treatment and Research, 2200 Santa Monica Blvd., 90404, Santa Monica, California, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 377-382 0340-7004 34:6<377 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer